Trending at Lumira Ventures

Lumira portfolio company, G1 Therapeutics, Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)

Altamash Hashmi G1 Therapeutics, Portfolio News

– PRESERVE 2 Will Evaluate Survival Benefit of COSELA in 250 Patients with Locally Advanced Unresectable or Metastatic TNBC RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced …

G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer

Altamash Hashmi G1 Therapeutics, Portfolio News

– Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically Relevant Endpoints Across Multiple Hematopoietic Lineages, Including Hematologic Adverse Events, Laboratory Values, and Use of Supportive Care Interventions – – Compared with Placebo, Administering COSELA Prior …

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors

Altamash Hashmi Iterion Therapeutics, Portfolio News

– Data provides springboard to advance three additional clinical programs evaluating Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) and pediatric cancers. HOUSTON, April 13, 2021 /PRNewswire/ — Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel …

Lumira completes investment in XyloCor Therapeutics’ Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

admin Portfolio News, Xylocor Therapeutics

XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease – Company closes additional $22.6 million in new financing – – Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as …

Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

Abi Kumar Fusion Pharmaceuticals, Portfolio News

Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Solid Tumors HAMILTON, ON and BOSTON, March 2, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as …

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Abi Kumar G1 Therapeutics, Portfolio News

COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy – Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, …

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Abi Kumar G1 Therapeutics, Portfolio News

Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutions RESEARCH TRIANGLE PARK, N.C. and RIDGEFIELD, Conn., March 02, 2021 …